Loading stock data…
ProKidney Corp (PROK)
$2.04+0.15 (+7.94%)
After Hours$2.01-0.03 (-1.45%)· Last close Jun 30
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ProKidney Corp. in the Healthcare sector is trading at $2.04 with a market capitalization of $497M. Wall Street consensus targets $6.25 (6 analysts), implying a +206.4% move over the next 12 months. The stock is currently 71% below its 52-week high of $7.13, remaining 8.1% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals. Risk note: RSI 77 is overbought against a weak tape. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +206.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 77 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $226,000↑ | $225,000↑ | $217,000↓ | $221,000↓ | $230,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$44.93M↑ | -$45.37M↓ | -$38.54M↑ | -$39.71M↑ | -$41.39M |
| Net Income | -$20.04M↓ | -$19.23M↓ | -$16.47M↑ | -$16.55M↑ | -$16.73M |
Peer Comparison
JNJUNHPFE
Fundamentals
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal c...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$496.89M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
7.06%
Volume
Today's trading volume
3.57M
Recent News
Why ProKidney (PROK) Is Building Its Bull Case Around Rilparencel’s Accelerated Approval Path
ProKidney Corp. (NASDAQ:PROK) is one of the small-cap stocks with potential to rise 1000 percent. The company’s main story centers on rilparencel, its experimental cell therapy for patients with advanced chronic kidney disease and type 2 diabetes. On May 15, ProKidney said it remained on track to finish enrolling patients for an important part of […]
Identiv And Two Other Penny Stocks To Watch Closely
The market remained flat over the last week, but it is up 26% over the past year, with earnings forecast to grow by 16% annually. For investors willing to look beyond the big names, penny stocks can present intriguing opportunities for growth at lower price points. While often associated with smaller or newer companies, these stocks can offer potential upside when backed by strong fundamentals and sound balance sheets.
ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates
PROKIDNEY CP (PROK) delivered earnings and revenue surprises of -7.69% and +222.86%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -15.09% and +2.01%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Beats Revenue Estimates
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of +14.48% and +3.34%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?